Kidney function predicts the rate of bone loss in older individuals: The Cardiovascular Health Study

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 61, Issue 7, 2006, Pages 743-748

  Fried, Linda F ^a,b   Shlipak, Michael G ^a,c   Stehman Breen, Catherine ^d   Mittalhenkle, Anuja ^e   Seliger, Stephen ^f   Sarnak, Mark ^g   Robbins, John ^h   Siscovick, David ⁱ   Harris, Tamara B ^j   Newman, Anne B ^b,k   Cauley, Jane A ^k  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AMGEN INC   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j NATIONAL INSTITUTE ON AGING   (United States)

^k UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C;

AGED; ARTICLE; BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; HIP; HUMAN; KIDNEY FUNCTION; LEAN BODY WEIGHT; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PRIORITY JOURNAL; WEIGHT REDUCTION;

EID: 33746630862     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/61.7.743     Document Type: Article

References (31)

1. Stehman-Breen C. Bone mineral density measurements in dialysis patients. Semin Dial. 2001;14:228-229.
2. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999;56:1084-1093.
3. Hsu CY, Cummings SR, McCulloch CE, Chertow GM. Bone mineral density is not diminished by mild-moderate renal insufficiency. Kidney Int. 2002;61:1814-1820.
4. Brzin J, Popovic T, Turk V, Borchart U, Machleidt W. Human cystatin, a new protein inhibitor of cysteine proteinases. Biochem Biophys Res Commun. 1984;118:103-109.
5. Fliser D, Ritz E. Serum cystatin-C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis. 2001;37:79-83.
6. Norlund L, Fex G, Lanke J, et al. Reference intervals for the glomerular filtration rate and cell-proliferation markers: serum cystatin-C and serum beta 2-microglobulin/cystatin-C-ratio. Scand J Clin Lab Invest. 1997;57:463-470.
7. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol, 1991;1:263-276.
8. Lui LY, Stone K, Cauley JA, Hillier T, Yaffe K. Bone loss predicts subsequent cognitive decline in older women: the Study of Osteoporotic Fractures, J Am Geriatr Soc. 2003;51:38-43.
9. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995;41:264-270.
10. Erlandsen EJ, Randers E, Kristensen JH. Evaluation of the Dade Behring N Latex Cystatin-C assay on the Dade Behring Nephelometer II System. Scand J Clin Lab Invest. 1999;59:1-8.
11. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification: evaluation of laboratory measurements for clinical assessment of kidney disease. Am J Kidney Dis. 2002;40(Suppl 1):S76-S111.
12. Taylor HL, Jacobs DR, Schucker B, Knudsen J, Leon AS, Debacker G. A questionnaire for the assessment of leisure time physical activities. J Chronic Dis. 1978;31:741-755.
13. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santoro AC. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med. 1996;101:488-501.
14. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of spine, hip and total body over 3 years in postmenopausal women with osteoporosis. Bone. 1996;18:141-150.
15. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604-610.
16. Randers E, Erlandsen EJ, Pedersen OL, Hasling C, Danielsen H. Serum cystatin-C as an endogenous parameter of the renal function in patients with normal to moderately impaired kidney function. Clin Nephrol. 2000;54:203-209.
17. Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K. Estimation of glomerular filtration rate in the elderly: a comparison of creatinine-based formulae with serum cystatin-C. J Int Med. 2004;256:70-78.
18. Kanis JA, Johnell O, Oden A, De Laet C, Mellstrom D. Diagnosis of osteoporosis and fracture threshold in men. Calcif Tissue Int. 2001;69:218-221.
19. Poor G, Atkinson EJ, O'Fallon WM, Melton LJ. Predictors of hip fracture in elderly men. J Bone Miner Res. 1995;10:1900-1907.
20. Lombardi A, Ross PD. The assessment of bone mass in men. Calcif Tissue Int. 2001;69:222-224.
21. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl 3):S1-S201.
22. Stehman-Breen C. Osteoporosis and chronic kidney disease. Semin Nephrol. 2004;24:78-81.
23. Leidig-Bruckner G, Ziegler R. Diabetes mellitus: a risk factor for osteoporosis? Exp Clin Endocrinol Diabetes. 2001;109(Suppl 2): S493-S514.
24. Salamone LM, Whiteside T, Friberg D, Epstein RS, Kuller LH, Cauley JA. Cytokine production and bone mineral density at the lumbar spine and femoral neck in premenopausal women. Calcif Tissue Int. 1998;63:466-470.
25. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and pro-coagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87-92.
26. Ensrud KE, Ewing SK, Stone KL, et al. Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women. J Am Geriatr Soc. 2003;51:1740-1747.
27. Hannan MT, Felson DT, Dawson-Hughes B, et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res. 2000;15:710-720.
28. van Meurs JBJ, Dhonukshe-Rutten RAM, Pluijm SMF, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350:2033-2041.
29. McLean RR, Jaques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fractures in older persons. New Engl J Med. 2004;350:2042-2049.
30. Cobum JW, Elangovan L. Prevention of metabolic bone disease in the pre-end-stage renal disease setting. J Am Soc Nephrol. 1998;9(12 Suppl):S71-S77.
31. Physician's Desk Reference. Montvale, NJ: Thomson PDR; 2004.